Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops noninvasive diagnostic tests for lung cancer and other lung diseases, with recurring news centered on its CyPath® Lung sputum-based diagnostic. Company updates describe clinical case studies, physician education, pulmonary nodule management, commercialization of the test, and laboratory services provided through Precision Pathology Laboratory Services.
News also covers bioAffinity’s flow cytometry and automated analysis platform, including research directed at asthma and chronic obstructive pulmonary disease diagnostics. The company reports developments involving clinical studies, scientific presentations, test adoption, revenue trends, equity financings, and the use of CyPath® Lung as a Laboratory Developed Test under CLIA oversight.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) will report its financial results for Q4 2022 on March 31, 2023, after market close. A conference call is scheduled for April 3, 2023, at 9:00 a.m. EDT to discuss these results. The company focuses on non-invasive cancer diagnostics and targeted treatments, highlighting its product CyPath® Lung, which is designed to detect early-stage lung cancer with high sensitivity and specificity. Future growth may depend on advancements in its therapeutic developments and the success of its revenue-generating products.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has announced the appointment of Julie Anne Overton as the new Director of Communications. The company is leveraging the expertise of Havas Health & You and Trinity Life Sciences to enhance the brand identity and commercialization of its non-invasive lung cancer detection test, CyPath® Lung. This strategic partnership aims to create a patient-friendly diagnostic tool for physicians. CyPath® Lung has demonstrated a 92% sensitivity and 87% specificity in clinical trials, showcasing significant potential in the oncology sector.
bioAffinity Technologies has published results demonstrating that its non-invasive test, CyPath® Lung, can detect early-stage lung cancer with 92% sensitivity and 87% specificity in high-risk patients, significantly outperforming existing methods. The study published in Respiratory Research emphasized the importance of accurately predicting cancer in patients with small pulmonary nodules. The testing method relies on automated analysis and machine learning, allowing for rapid sample processing without the need for expert evaluation. This innovative approach is poised to enhance screening accuracy and is crucial for patient certainty.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) announced a Notice of Allowance from the USPTO for a patent on porphyrin compounds aimed at targeted cancer treatments. The patent, set to last until 2037, is held by its subsidiary OncoSelect. With over 1.9 million new cancer cases projected in the U.S. for 2022 and cancer care costs soaring to $150.8 billion in 2018, the company emphasizes the need for more precise treatments to enhance patient survival and quality of life. bioAffinity is also advancing its non-invasive lung cancer diagnostic system, CyPath® Lung, which boasts high sensitivity and specificity.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced key promotions and new hires aimed at enhancing its diagnostics division focused on early-stage lung cancer detection. Jennifer Rebeles, Ph.D., has been promoted to Vice President of Diagnostics, leading the development of CyPath® Lung, an advanced non-invasive test. Additionally, new research scientists Rossella Titone, Ph.D., and Alvaro Souto Padron de Figueiredo, Ph.D., have joined the team. The company emphasizes its commitment to innovation in lung disease diagnostics and cancer treatment.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) reports advancements in cancer treatment research. At the Cell Bio conference in Washington, D.C. from December 3-7, 2022, Dr. David Elzi will present his findings on silencing two genes, CD320 and LRP2, to target cancer cells while sparing normal cells. This research supports the development of their therapeutic platforms and aims to enhance understanding of gene silencing in cancer treatment. The company continues to advance its CyPath® Lung test for early-stage lung cancer diagnosis.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) successfully completed a $15.6 million IPO, enhancing its funding for noninvasive cancer diagnostics and therapeutics. The company achieved patent awards in China, Mexico, and Australia for novel cancer treatment compounds, and commenced a limited launch of its CyPath® Lung product in San Antonio. Financially, bioAffinity reported $1,150 in revenue for Q3 2022, with a net loss of $4.6 million. Despite a revenue increase from the previous year, the company’s administrative expenses rose significantly, indicating challenges in managing costs post-IPO.
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) has expanded its Scientific and Medical Advisory Board with the addition of Dr. Sheila Habib and Dr. David Hill. Their expertise in lung cancer diagnostics will enhance ongoing research and development efforts, particularly with the CyPath® Lung test, which boasts a sensitivity of 92% and specificity of 87% for early-stage lung cancer detection. This strategic move aims to leverage their groundbreaking work in enhancing early diagnosis, crucial for improving treatment outcomes.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced a conference call and audio webcast on November 14, 2022, at 8 a.m. ET to discuss its third-quarter 2022 financial and corporate results. The call is accessible via the company's Investor Relations website. bioAffinity is focused on noninvasive early-stage cancer diagnosis and targeted treatment, with its primary product, CyPath® Lung, demonstrating high sensitivity for early lung cancer detection. The company is involved in ongoing research at The University of Texas at San Antonio.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) recently announced the award of multiple patents in China, Mexico, and Australia for novel porphyrin conjugated compounds aimed at selective cancer treatment. These patents, valid until 2037, underscore the company's commitment to innovative cancer therapies, particularly as cancer rates rise in these regions. The company’s flagship product, CyPath® Lung, shows high sensitivity and specificity in early lung cancer detection, indicating strong potential for both diagnostic and therapeutic advancements in oncology.